Naegis has assembled a team with expertise in small molecule drug discovery and models of inflammatory disease.  Selecting biochemical targets of high interest in numerous diseases, the team has designed several libraries of drug-like small molecules that have potential for advancement for the treatment of a number of serious inflammatory conditions.  Initially focused on ocular diseases, selected based on unmet need and the high relevance of the biochemical target, the team has now identified a series of lead compounds which have demonstrated activity against the molecular target, and shown activity in models of inflammatory disease. 

Leukotrienes: Key mediators of inflammatory disease

Naegis’s compounds block the production of leukotrienes, pro-inflammatory mediators that are elevated in patients with inflammatory conditions, including ocular diseases such as allergic conjunctivitis and uveitis.  It’s lead compound, N0651, is effective in ocular models of uveitis, including experimental autoimmune uveitis and endotoxin-induced uveitis , and distributes to the back of the eye (retina) upon topical application as an eye drop.  Based on the observations from preclinical studies the company believes  N0651 has the potential to be a safe and effective treatment for patients with serious inflammatory eye disease.    

The company has developed a strong intellectual property position within the class and is now advancing its lead compound, N0651, towards clinical development.

Top
We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…